Identifying factors for pembrolizumab eligibility in head and neck cancer.
Saved in:
| Title: | Identifying factors for pembrolizumab eligibility in head and neck cancer. |
|---|---|
| Authors: | Miyamaru S; Department of Otolaryngology-Head and Neck Surgery, Graduate School of Medicine, Kumamoto University, 1-1-1, Honjo, Chuo-ku, Kumamoto, 860-8556, Japan. smiyamaru@gmail.com., Murakami D; Department of Otolaryngology-Head and Neck Surgery, Graduate School of Medicine, Kumamoto University, 1-1-1, Honjo, Chuo-ku, Kumamoto, 860-8556, Japan., Nishimoto K; Department of Otolaryngology-Head and Neck Surgery, Graduate School of Medicine, Kumamoto University, 1-1-1, Honjo, Chuo-ku, Kumamoto, 860-8556, Japan., Orita Y; Department of Otolaryngology-Head and Neck Surgery, Graduate School of Medicine, Kumamoto University, 1-1-1, Honjo, Chuo-ku, Kumamoto, 860-8556, Japan. |
| Source: | Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2025 Feb 07; Vol. 151 (2), pp. 67. Date of Electronic Publication: 2025 Feb 07. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 7902060 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-1335 (Electronic) Linking ISSN: 01715216 NLM ISO Abbreviation: J Cancer Res Clin Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
